Overview
Overview
SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide originally developed as a cosmeceutical ingredient for anti-wrinkle effects[1][2]. It is an extended analog of the hexapeptide Argireline, designed to mimic part of the SNAP-25 protein involved in neuromuscular signaling[5]. By competitively inhibiting SNAP-25 in the SNARE complex, SNAP-8 attenuates acetylcholine release at neuromuscular junctions, thereby relaxing facial muscle contractions without causing paralysis[1][5]. This educationa
- Category
- Longevity
- Routes
- subcutaneous
Mechanism
SNAP-8
Mechanism of action
Mechanism of action
SNAP-8 is an extended analog of Argireline (hexapeptide) designed to mimic the SNAP-25 protein, which plays a crucial role in neurotransmitter release [1] [2] . By competitively inhibiting SNAP-25 in the SNARE complex, SNAP-8 reduces acetylcholine release at neuromuscular junctions, leading to gentle muscle relaxation [5] . Unlike botulinum toxin (Botox) which cleaves SNAP-25 and causes muscle paralysis, SNAP-8 provides a milder, non-paralyzing effect that preserves natural facial expressions while reducing the depth of expression lines [1] [5] . Preclinical studies showed SNAP-8 demonstrated approximately 30% greater activity than Argireline in reducing neurotransmitter release, with enhanced formulation stability [5] .
Key research findings
- 01
Synthetic acetylated octapeptide (INCI name Acetyl Octapeptide-3; also called acetyl glutamyl heptapeptide-1), developed as a topical cosmetic peptide and an elongated analog of the hexapeptide 'Argireline' line.
- 02
Mechanism (in vitro): mimics the N-terminal domain of SNAP-25 and competes within the SNARE complex, reported to reduce neurotransmitter (catecholamine/acetylcholine) release at the neuromuscular junction.
- 03
Distinct from botulinum toxin: described as a reversible, competitive action, whereas botulinum toxin irreversibly cleaves SNAP-25.
- 04
In vitro cosmetic-science work reported substantial reductions in neurotransmitter release in cell models.
- 05
Studied for topical cosmetic use (appearance of expression lines); independent peer-reviewed clinical data are limited and largely industry-associated. Designed as a topical ingredient, not an injectable.
Primary source: The primary research is largely in vitro and cosmetic-formulation work from the developing industry (Lipotec/IQAC), with limited independent peer-reviewed clinical literature. The SNARE/SNAP-25 mechanism is well described conceptually, but human efficacy data are modest.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Reduces wrinkle depth by an average of approximately 35%, with maximal improvements approaching 60% in certain areas after 28–30 days of consistent application in topical studies[5].
Protocol Reference
Protocol reference
Commonly cited research range: 330–1000 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–4
330 mcg (0.33 mg)
Weeks 5–8
500 mcg (0.50 mg)
Weeks 9–12
1,000 mcg (1.0 mg)
Weeks 13–16 (Optional)
1,000 mcg (1.0 mg)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–4 | 330 mcg (0.33 mg) | 10 units (0.10 mL) |
| Weeks 5–8 | 500 mcg (0.50 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1,000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 (Optional) | 1,000 mcg (1.0 mg) | 30 units (0.30 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure [8] .
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days for maximum potency [8] .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Do not refreeze reconstituted solution; prepare aliquots if needed.
Clinical Evidence
Clinical evidence
Studied primarily as a topical cosmeceutical for the appearance of expression lines; evidence is largely formulation/cosmetic research.
The primary research is largely in vitro and cosmetic-formulation work from the developing industry (Lipotec/IQAC), with limited independent peer-reviewed clinical literature. The SNARE/SNAP-25 mechanism is well described conceptually, but human efficacy data are modest.
- 01Synthetic acetylated octapeptide (INCI name Acetyl Octapeptide-3; also called acetyl glutamyl heptapeptide-1), developed as a topical cosmetic peptide and an elongated analog of the hexapeptide 'Argireline' line.
- 02Mechanism (in vitro): mimics the N-terminal domain of SNAP-25 and competes within the SNARE complex, reported to reduce neurotransmitter (catecholamine/acetylcholine) release at the neuromuscular junction.
- 03Distinct from botulinum toxin: described as a reversible, competitive action, whereas botulinum toxin irreversibly cleaves SNAP-25.
- 04In vitro cosmetic-science work reported substantial reductions in neurotransmitter release in cell models.
- 05Studied for topical cosmetic use (appearance of expression lines); independent peer-reviewed clinical data are limited and largely industry-associated. Designed as a topical ingredient, not an injectable.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to SNAP-8.
- 01International Journal of Cosmetic Science — Argireline hexapeptide with antiwrinkle activity (human study; 10% cream reduced wrinkle depth ~30% after 30 days) View Source
- 02Journal of Analytical Science and Technology — Method development for acetyl octapeptide-3 (SNAP-8) analysis by LC-MS/MS; stability and analytical characterization View Source
- 03Journal of Drugs in Dermatology — Open-label 14-week trial of multi-peptide serum (including SNAP-8); statistically significant smoothing of expression lines with good tolerability View Source
- 04Annals of Dermatology — Clinical safety and efficacy evaluation of dissolving microneedle patch containing SNAP-8; 24-subject trial showed significant wrinkle reduction and improved elasticity over 4 weeks with no adverse effects View Source
- 05Frontiers in Chemistry — Cosmeceutical peptides review; SNAP-8 mechanism (SNARE complex inhibition), ~30% greater activity than Argireline, and enhanced stability View Source
- 06Advances in Therapy — Subcutaneous injection of drugs: literature review of factors influencing pain sensation; fine gauge needles and small volumes minimize discomfort View Source
- 07MedlinePlus (NLM/NIH) — Subcutaneous injection patient instructions; technique, site selection, and rotation guidance View Source
- 08GenScript Technical Resources — Peptide storage and handling guidelines; lyophilized storage at −20 °C, reconstituted refrigeration, and stability considerations View Source
- 09CDC — Vaccine administration: subcutaneous route guidance (angle, site, and technique) View Source
- 10CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections View Source
- 11NCBI Bookshelf — Best practices for injection technique (asepsis, preparation, administration, and site rotation) View Source
- 12Pure Lab Peptides — SNAP-8 (10 mg) product page (quality, batch documentation, and supplier information) View Source
Observed Effects
Observed effects in cited research
Reported
- A 24-subject clinical trial using dissolving microneedle patches containing SNAP-8 showed significant reduction in eye wrinkles and improved skin elasticity over 4 weeks, with no adverse effects reported[4].
- An open-label 14-week study of a multi-peptide serum including SNAP-8 noted statistically significant smoothing of expression lines with good tolerability and no serio
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Studied primarily as a topical cosmetic ingredient; systemic research data are limited. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| SNAP-8this | A synthetic acetylated octapeptide (an extended Argireline analog) studied for topical reduction of muscle contraction by interfering with SNARE-complex formation at the neuromuscular junction. | subcutaneous | Investigational / RUO |
| SS-31 | A mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron-transport-chain organization and reducing reactive oxygen species. | subcutaneous | Investigational / RUO |
| Testagen | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Gly) studied for modulation of endocrine function, particularly pituitary-gonadal regulatory pathways. | subcutaneous | Investigational / RUO |
| Vesugen (Lys-Glu-Asp) | A synthetic tripeptide bioregulator (Lys-Glu-Asp) studied for gene-regulatory support of vascular endothelial tissue. | subcutaneous | Investigational / RUO |
| Vilon | A synthetic immunoregulatory dipeptide (Lys-Glu) studied for gene-regulatory and immunomodulatory activity, including effects on lymphocyte markers and chromatin structure. | subcutaneous | Investigational / RUO |
| Survodutide | An investigational long-acting dual agonist of GLP-1 and glucagon receptors studied for appetite regulation and increased energy expenditure. | subcutaneous | Investigational / RUO |
| TB-500 | Upregulates actin, promotes cell migration, reduces inflammation, and stimulates wound healing and tissue repair. | subcutaneous, intramuscular | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
SNAP-8 is a synthetic acetylated octapeptide (Acetyl Octapeptide-3) developed as a topical cosmetic peptide. It is an elongated relative of the Argireline (acetyl hexapeptide) line and is handled here as a Research Use Only material.
In vitro, SNAP-8 mimics a fragment of the SNAP-25 protein and competes within the SNARE complex, which research reports reduces neurotransmitter release at the neuromuscular junction.
Research describes SNAP-8 as a reversible, competitive action applied topically, in contrast to botulinum toxin, which is injected and irreversibly cleaves SNAP-25. They are different categories of material.
Mechanistic work is largely in vitro (cosmetic-science labs). Independent peer-reviewed clinical data are limited and mostly industry-associated.
Store the lyophilized peptide desiccated and protected from light; keep reconstituted/formulated solutions cold and follow the protocol reference and product documentation.
Acetyl Octapeptide-3 appears as a cosmetic ingredient in some products in certain jurisdictions; research-grade material on this platform is handled as Research Use Only and is not intended for human or veterinary use. This is not medical advice.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.